Therapy with Skyrizi is 600mg given by infusion at weeks zero, four and eight, followed by a 360mg subcutaneous shot given at week 12 and every eight weeks thereafter. The FDA is also reviewing a ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi benefitted from an additional 12 weeks of treatment, according to study ...

New data with AbbVie’s IL-23 inhibitor Skyrizi suggests it can alleviate symptoms in psoriasis patients who don’t respond well to other biologics for the skin disease, including widely-used IL ...